Literature DB >> 3306994

Piperacillin and a combination of clindamycin and gentamicin for the treatment of hospital and community acquired acute pelvic infections including pelvic abscess.

D L Hemsell, P G Hemsell, M C Heard, B J Nobles.   

Abstract

Therapy for acute polymicrobial pelvic infections is empiric and must include predictable anaerobic coverage. Single agent therapy, if effective, is advantageous for the patient, nurses, pharmacy and hospital. Piperacillin sodium was compared with a combination of clindamycin and gentamicin as therapy for 63 female patients who were hospitalized with acute pelvic infections including pelvic abscess complicating community acquired salpingitis. Over-all clinical efficacy with piperacillin was 96.8 per cent and 90.3 per cent for clindamycin and gentamicin. Fewer bacteria demonstrated in vitro resistance to piperacillin (p = 0.008) and the cost of treatment for these infections was significantly less with piperacillin (p less than 0.05). Serious adverse reactions were not observed with either regimen. Piperacillin provides effective, cost-efficient therapy for women with acute polymicrobial pelvic infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306994

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  3 in total

1.  In vitro synergy of clindamycin and aminoglycosides against Chlamydia trachomatis.

Authors:  M D Pearlman; S Faro; G D Riddle; G Tortolero
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Antibiotic therapy for pelvic inflammatory disease.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Jackson Maissiat; Rui V Duarte; Jonathan Ross
Journal:  Cochrane Database Syst Rev       Date:  2020-08-20

3.  Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin.

Authors:  D L Hemsell; G D Wendel; P G Hemsell; M L Heard; B J Nobles
Journal:  Infect Dis Obstet Gynecol       Date:  1993
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.